文献速递哮喘

度普利尤单抗对中重度哮喘患者黏液负荷的影响:VESTIGE试验

Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01

VESTIGE试验纳入血嗜酸性粒细胞≥300 cells/μL且FeNO≥25 ppb的中重度哮喘成人,随机接受度普利尤单抗300 mg(n=72)或安慰剂(n=37)每2周一次治疗24周。事后分析显示,度普利尤单抗降低高黏液栓评分患者比例(32.8% vs 67.2%),并改善肺功能,且不论基线黏液栓评分如何均更易达到FeNO<25 ppb。

要点

  • 度普利尤单抗治疗24周后高黏液栓评分患者比例由67.2%降至32.8%。
  • 高黏液栓评分亚组中,度普利尤单抗显著改善支扩前后FEV1%预计值及支扩前FVC。

核心结论

  • 度普利尤单抗可降低中重度哮喘患者黏液栓评分,并在高基线黏液栓评分患者中改善肺功能。
  • 度普利尤单抗增加达到FeNO<25 ppb的可能性,且不受基线黏液栓评分影响。

研究设计与样本

  • VESTIGE(NCT04400318)为随机对照试验,纳入中重度哮喘成人,基线血嗜酸性粒细胞≥300 cells/μL且FeNO≥25 ppb。
  • 患者接受度普利尤单抗300 mg(n=72)或安慰剂(n=37)每2周一次,治疗24周。
  • 事后分析包括黏液栓评分自基线变化,以及按基线黏液栓评分(高:≥4;低:0-3.5,基于高分辨率CT)分层分析FeNO<25 ppb比例、FEV1%预计值和FVC。

主要发现

  • 度普利尤单抗组第24周高黏液栓评分患者比例低于基线(32.8% vs 67.2%),安慰剂组比例相似(76.7% vs 73.3%)。

关键数值与推荐

  • 高黏液栓评分定义为评分≥4,低评分定义为0-3.5,基于高分辨率CT。
  • 度普利尤单抗300 mg每2周一次,治疗24周。
  • 纳入标准:中重度哮喘成人,基线血嗜酸性粒细胞≥300 cells/μL,FeNO≥25 ppb。

临床怎么用

  • 对于中重度哮喘伴高黏液栓负荷患者,度普利尤单抗可能减少黏液栓并改善肺功能。
  • 度普利尤单抗增加达到FeNO<25 ppb的可能性,可作为评估治疗反应的参考指标之一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Chronic mucus hypersecretion contributes to airway obstruction in asthma. OBJECTIVES: To assess dupilumab efficacy by baseline mucus plug score. METHODS: In VESTIGE (NCT04400318), adults with moderate-to-severe asthma, baseline blood eosinophils ≥300 cells/μL, and fractional exhaled nitric oxide (FeNO) ≥25 ppb received dupilumab 300 mg (n = 72) or placebo (n = 37) every 2 weeks for 24 weeks. Post hoc analyses included mucus plug score change from baseline, and patient proportion achieving FeNO <25 ppb, percent predicted FEV1, and FVC stratified by baseline mucus plug score (high/low defined by score ≥4 or 0-3.5, respectively, derived from high-resolution computed tomography scans). MEASUREMENTS AND MAIN RESULTS: Fewer dupilumab-receiving patients had high mucus plug score at week 24 than at baseline (32.8% vs 67.2%); proportions remained similar in placebo-receiving patients (76.7% vs 73.3%). Dupilumab versus placebo recipients were more likely to achieve FeNO <25 ppb in high-/low-mucus-plug score subgroups (odds ratio, 6.64; P = .003/8.54; P = .024). Dupilumab versus placebo significantly increased pre-/post-bronchodilator percent predicted FEV1 (least squares mean difference [LSMD], 16.77 percentage points [95% CI, 9.81-23.73]; P <.0001 [pre] and 12.70 [95% CI, 3.87-21.52]; P = .0055 [post]) and pre-bronchodilator FVC (LSMD, 0.42 mL [95% CI, 0.17-0.66]; P = .001), and numerically improved post-bronchodilator FVC (LSMD, 0.30 mL [95% CI, 0.01-0.59]; P = .0399) in the high-mucus-plug score subgroup. CONCLUSIONS: Dupilumab reduced mucus plug scores and improved lung function in patients with moderate-to-severe asthma with high baseline mucus plug score, and increased the likelihood of achieving FeNO <25 ppb regardless of baseline mucus plug score.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Porsbjerg C, Dunican EM, Lugogo NL, et al. Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial. Am J Respir Crit Care Med. 2026. PMID: 41145399. doi:10.1164/rccm.202410-1894OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。